MENLO PARK, CA, USA I September 21, 2017 I Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is ...
MENLO PARK, CA, USA I September 21, 2017 I Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is ...
These future therapies will be based on Bicycle's proprietary peptide development platform. “We believe our Bicycle platform has extremely broad ...
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM--(Marketwired - Sep 20, 2017) - Treos Bio Limited, which is developing precision peptide ...
PTG-300 is an injectable hepcidin mimetic peptide, discovered using the company's proprietary technology platform. Protagonist is developing ...
Swiss pharmaceutical supplier Lonza Group AG (LONN.S) last year said it would buy Capsugel, a U.S. maker of capsules and other drug delivery ...
CAMBRIDGE, MA, USA I September 18, 2017 I Thrombolytic Science, LLC (TSI), a clinical stage vascular health and biotechnology company, today ...
LEUVEN, Belgium I September 18, 2017 I ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for ...
PARIS, France I September 18, 2017 I Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) ...
Results showed the once-weekly glucagon-like peptide-1 (GLP-1) agonist Bydureon did not increase the risk of a major adverse cardiovascular event ...
Bicycle Therapeutics is developing a new class of medicines to fight cancer and other diseases using its proprietary bicyclic peptide, or 'Bicycle', ...